Patents by Inventor Stelios Tzannis

Stelios Tzannis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080031966
    Abstract: The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.
    Type: Application
    Filed: February 7, 2007
    Publication date: February 7, 2008
    Inventors: Stelios Tzannis, Nancy Dasovich, Sandeep Kumar, Negar Sadrzadeh
  • Publication number: 20070207207
    Abstract: Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.
    Type: Application
    Filed: January 5, 2007
    Publication date: September 6, 2007
    Applicant: AcelRx Pharmaceuticals, Inc.
    Inventors: Stelios Tzannis, Pamela Palmer, Thomas Schreck, Larry Hamel, Andrew Poutiatine
  • Patent number: 7192919
    Abstract: The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: March 20, 2007
    Inventors: Stelios Tzannis, Nancy Dasovich, Sandeep Kumar, Negar Sadrzadeh
  • Publication number: 20070031342
    Abstract: A composition of microparticles for delivery to the pulmonary system provides sustained release of a pharmaceutical agent. The microparticles comprise a lipid structural matrix comprising a multilamellar structure of lipid bilayers having lipid chains ordered in an L?L phase. The lipid matrix at least partially encapsulates the pharmaceutical agent at a bilayer interface formed between head groups of adjacent lipid layers. The microparticles are prepared by heating a precursor formulation comprising a solvent, matrix-forming excipient and pharmaceutical agent to a temperature above the liquid-crystalline transition temperature Tc of the matrix-forming excipient and below the melting or denaturation point of the pharmaceutical agent. The solvent is then removed to form microparticles with partially encapsulated pharmaceutical agent.
    Type: Application
    Filed: May 9, 2006
    Publication date: February 8, 2007
    Inventors: Stelios Tzannis, Negar Sadrzadeh, Helen Schiavone, Renee Labiris
  • Publication number: 20050214224
    Abstract: A pharmaceutical formulation for pulmonary administration is disclosed. The pharmaceutical formulation comprises a lipid component and an active agent, wherein the pharmaceutical formulation has a liquid phase transition temperature of less than or equal to 37° C. when hydrated and a liquid phase transition temperature of greater than 57° C. when non-hydrated, whereby the lipid component spontaneously encapsulates and/or entraps the active agent when the pharmaceutical formulation is administered to the lungs. A targeting agent may also be provided. In one version, the pharmaceutical formulation is useful to treat an infection, such as an inhalation anthrax infection.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 29, 2005
    Applicant: Nektar Therapeutics
    Inventors: Jeffry Weers, Thomas Tarara, Stelios Tzannis
  • Publication number: 20050203002
    Abstract: The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.
    Type: Application
    Filed: January 7, 2005
    Publication date: September 15, 2005
    Inventors: Stelios Tzannis, Nancy Dasovich, Sandeep Kumar, Negar Sadrzadeh
  • Publication number: 20050053666
    Abstract: A composition is provided comprising antibody-containing particles. These particles can be used to form antibody-containing powders useful for reconstitution with a suitable diluent. The reconstituted compositions, in turn, comprise an antibody in an amount suited for delivery by injection, such as subcutaneous injection. Methods for preparing the various compositions as well as methods of use are also provided.
    Type: Application
    Filed: November 14, 2003
    Publication date: March 10, 2005
    Inventors: Stelios Tzannis, Robert Platz, Bhas Dani